Bicara Therapeutics Inc. (BCAX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Claire Mazumdar Clemon M.B.A., Ph.D.
|
CEO & Director | 927.69k | -- | 1989 |
|
Mr. Ryan Cohlhepp Pharm.D.
|
President, COO & Director | 858.4k | -- | 1977 |
|
Ms. Jennifer Larson
|
CFO, Treasurer & Principal Accounting Officer | -- | -- | 1975 |
|
Ms. Rachel Frank
|
Vice President of Investor Relations and Corporate Communications | -- | -- | -- |
|
Ms. Lara S. Meisner J.D.
|
Chief Legal Officer, Compliance Officer & Corporate Secretary | -- | -- | 1972 |
|
Ms. Pauline Dufresne
|
Chief People Officer | -- | -- | -- |
|
Ms. Rachel Salazar
|
SVP of R&D Strategy and Operations | -- | -- | -- |
|
Ms. Sathish Hasige Ph.D.
|
Senior VP and Head of Technical Operations & Supply Chain | -- | -- | -- |
|
Ms. Angela Windt
|
VP & Head of Regulatory Affairs | -- | -- | -- |
|
Dr. Jeltje Schulten M.B.A., M.D.
|
Senior Vice President of Clinical & Medical Affairs | -- | -- | -- |
Bicara Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 103
Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Corporate Governance
Upcoming Events
November 10, 2026 at 12:30 PM UTC
Bicara Therapeutics Inc. Earnings Date
